Does Rallies show 13F holders for FOLD?

Yes. Rallies tracks hedge fund and 13F ownership data for FOLD, including fund names, share counts, latest tracked quarter, and position changes when available.

Is FOLD research on Rallies investment advice?

No. Rallies provides research, data, and educational context for FOLD. It does not provide personalized investment advice.

FOLD (Amicus Therapeutics, Inc) Stock Analysis - Hedge Fund Holdings

Amicus Therapeutics, Inc (FOLD) is a publicly traded Healthcare sector company. As of May 20, 2026, FOLD trades at $14.49 with a market cap of $4.55B and a P/E ratio of -161.00. FOLD moved +0.00% today. Year to date, FOLD is +47.11%; over the trailing twelve months it is +101.25%. Its 52-week range spans $5.51 to $14.50. Analyst consensus is buy with an average price target of $14.50. Rallies surfaces FOLD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns FOLD stock?

Hedge funds tracked by Rallies that own FOLD include Pentwater Capital, Soros Fund, Panagora Asset, Redmile Group, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amicus Therapeutics, Inc.

FOLD Key Metrics

Key financial metrics for FOLD
Metric	Value
Price	$14.49
Market Cap	$4.55B
P/E Ratio	-161.00
EPS	$-0.09
Dividend Yield	0.00%
52-Week High	$14.50
52-Week Low	$5.51
Volume	5.29M
Avg Volume	0
Revenue (TTM)	$634.21M
Net Income	$-27.11M
Gross Margin	88.50%

Top Hedge Funds Holding FOLD

Pentwater Capital holds 14.00M shares of FOLD, changed +21.74% as of Mar 31, 2026.
Soros Fund holds 5.75M shares of FOLD, changed +15.06% as of Mar 31, 2026.
Panagora Asset holds 1.45M shares of FOLD, changed +0.32% as of Sep 30, 2025.
Redmile Group holds 777.18K shares of FOLD, changed -34.64% as of Sep 30, 2025.
Orbimed Advisors holds 729.90K shares of FOLD, changed -55.64% as of Dec 31, 2025.

Latest FOLD News

BioMarin Completes $4.8bn Amicus Acquisition Adding Two Rare Disease Drugs — Apr 28, 2026
BioMarin Wins FDA Approval for Palynziq in Patients Aged 12+ With PKU — Mar 2, 2026
Amicus Q4 Revenue Beats on Galafold; BioMarin $4.8B Deal — Feb 23, 2026
Amicus Therapeutics' 2025 Revenue Up 17% to $634.2M, Q2 2026 BioMarin Deal — Feb 20, 2026
Amicus Therapeutics Sees 41.7% Surprise, Q4 Sales Estimated at $179.9M — Feb 16, 2026

Recent FOLD Insider Trades

Campbell Bradley L sold 22.50K (~$322.84K) on Mar 2, 2026.
Campbell Bradley L sold 75.00K (~$1.07M) on Jan 20, 2026.
Clark David Michael sold 25.64K (~$363.38K) on Dec 19, 2025.

FOLD Analyst Consensus

24 analysts cover FOLD: 0 strong buy, 16 buy, 7 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.50.

Common questions about FOLD

Who owns FOLD stock?: Hedge funds tracked by Rallies that own FOLD include Pentwater Capital, Soros Fund, Panagora Asset, Redmile Group, and Orbimed Advisors. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Amicus Therapeutics, Inc.
Does Rallies show 13F holders for FOLD?: Yes. Rallies tracks hedge fund and 13F ownership data for FOLD, including fund names, share counts, latest tracked quarter, and position changes when available.
Is FOLD research on Rallies investment advice?: No. Rallies provides research, data, and educational context for FOLD. It does not provide personalized investment advice.